One Case of Participation of Clinical Pharmacists in Treatment of Brucella Endocarditis

doi:10.19803/j.1672-8629.2020.12.18

Abstract

Abstract: Objective To investigate the role of clinical pharmacists in the treatment of infective endocarditis with brucella.Methods Clinical pharmacists, using their pharmaceutical expertise, participated in the process of anti-infection treatment, adverse reaction disposal and anticoagulant treatment of one patient while assisting physicians in formulating optimal drug treatment programs.Results The clinicians took the advice of clinical pharmacists, and the patients' condition was effectively controlled.Conclusion The participation of clinical pharmacists in clinical drug therapy can better promote rational clinical drug use and ensure the safety of drug use for patients.

Key words: brucellosis, endocarditis, clinical pharmacist, pharmaceutical care

CLC Number:

R969.3

YU Xiongjie, ZHANG Jing, LI Yuan, WANG Peng, HUANG Nianxu, CHEN Jinhua. One Case of Participation of Clinical Pharmacists in Treatment of Brucella Endocarditis[J]. Chinese Journal of Pharmacovigilance, 2020, 17(12): 930-933.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.2020.12.18

https://zgywjj.magtechjournal.com/EN/Y2020/V17/I12/930

References

[1] Chen HZ,Lin GW,Wang JY.Practice of Internal Medicine(实用内科学)[M].14th Ed.Beijing:People's Medical Publishing House,2013:529-532.
[2] Ministry of Health,PRC.Brucellosis Diagnosis and Treatment Guide (trial)[J].Information on infectious diseases(传染病信息),2012,25(6):323-324.
[3] Zhang W,BAI CY,ZHOU Q,et al.Analysis of blood culture characteristics of 4 cases of Brucella infection[J].Guangdong Medical Science(广东医学),2011,32(5):644-645.
[4] Reguera JM,Alarcon A,Miralles F,et al.Brucella endocarditis:clinical,diagnostic,and therapeutic approach[J].Eur J Clin Mierobiol Infect Dis,2003,22(11):647-650.
[5] Fan HW.The Sanford Guide to Antimicrobial Therapy (桑德福抗微生物治疗指南) [M].New Translation,48th edition.Beijing:Peking Union Medical College Press,2019:62.
[6] Ma XJ,Yang WJ.Anti-infective therapy and progress of infective endocarditis[J].Chinese Journal of Infection and Chemotherapy(中国感染与化疗杂志),2017,17(6):713-718.
[7] Chinese Society of Cardiovascular Medicine.Expert consensus on the prevention,diagnosis and treatment of infective endocarditis in adults[J].Chinese Journal of Cardiovascular Diseases(中华心血管病杂志),2014,42(10):806-816.
[8] Fan HW.The Sanford Guide to Antimicrobial Therapy (桑德福抗微生物治疗指南) [M].New Translation,48th edition.Beijing:Peking Union Medical College Press,2019:28.
[9] Dohmen PM,Guleri A,Capone A,et al.Daptomycin for the treatment of infective endocarditis:results from a European registry[J].J Antimicrob Chemother,2013,68(4):936-942.
[10] Uleri A,Utili R,Dohmen P,et al.Daptomycin for the treatment of infective endocarditis:results from European Cubicin,Outcomes Registry and Experience ( EU-CORE)[J].Infect Dis Ther,2015,4(3):283-296.
[11] Zou Q,Bu YL,Teng HS.Review of the literature on doxycycline adverse reactions[J].Chinese Journal of Drug Abuse Prevention(中国药物滥用防治杂志),2016,22(6):366-367.
[12] Shi W,Gu M,Ma SP.Literature analysis on the distribution characteristics of primary anti-tuberculosis drug adverse reactions[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2011,8(7):434-436.
[13] Liu M,Li ZD.A case study on the scoring method of drug-induced SJS or TEN -Naranjo score and ALDEN score[J].Chinese Journal of Drug Application and Surveillance(中国药物应用与监测杂志),2014,11(4):247-249.

[1]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[2]	LIANG Xiao, LI Li, XU Xiaolong, BAI Yinglu, YANG Yumei, ZHU Yong, LIU Qingquan. Advancements in Treatment of Brucellosis with Traditional Chinese Medicine [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 231-234.
[3]	LIU Nannan, XI Yalin, CHEN Zhe. One Case of Adrenocortical Insufficiency Caused by Cadonilimab [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 109-112.
[4]	ZHANG Caixia, ZHOU Yi, TAN Lu, CHEN Wenming, LIU Yang, YOU Yu. Pharmaceutical care of pulmonary aspergillus infection secondary to sepsis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1064-1067.
[5]	YAN Yan, LIU Naiyi, QIAO Ling, ZHANG Yi, YANG Chen. One case of fulminant type 1 diabetes mellitus induced by allopurinol tablets hypersensitivity syndrome [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1068-1070.
[6]	ZHANG Qian, YUN Yuan, HE Lian. Pharmaceutical care of hyperprolactinemia in a patient induced by risperidone [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 936-938.
[7]	LIN Yanxin, LIU Yanhui, DONG Jing, YAO Jiachen, LI Wenyan. Pharmaceutical care of acute liver injury in a patient with colon cancer induced by irinotecan [J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 693-696.
[8]	LI haiyan, YANG Zhongxu, LIU Yuekun, WANG Lihong. Pharmaceutical care of serious adverse reactions due to methotrexate treatment of ectopic pregnancy [J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 454-456.
[9]	LIU Qi, ZHANG Yufeng, LUO Hao, LI Xin. Analysis of the rationality and safety of clinical application of anrotinib in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 329-334.
[10]	JI Qiuxia, JIN Jian, ZHANG Bin. Pharmaceutical care for immune-related adverse events induced by toripalimab [J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 346-348.
[11]	FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
[12]	LIU Xin, WANG Guojun. Pharmacological Care of Hypertension Due to Glucocorticoid Drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(11): 1303-1305.
[13]	SHEN Jianghua, KONG Chao, PAN Fumin, CHU Yanqi. Pharmaceutical care of a case with vertebral osteomyelitis of Coxiella burnetiid [J]. Chinese Journal of Pharmacovigilance, 2024, 21(10): 1166-1168.
[14]	ZHANG Xialan, YUAN Jing, WU Bin, QIN Yuanyuan. Medications of apatinib mesylate in patients with malignant tumors [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 927-932.
[15]	WANG Ran, LI Yifan, LIU Xiaoyan, FENG Xin. One case of pharmaceutical care of drug exposure during pregnancy [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 933-934.